Literatur
Hench PS, Kendall EC, Slocumb CH et al (1949) The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Preliminary report. Proc Staff Meet Mayo Clin 24:181–197
Hench PS, Kendall EC, Slocumb CH, Polley HF (1949) Adrenocortical hormone in arthritis : preliminary report. Ann Rheum Dis 8:97–104
Hench PS (1950) The present status of cortisone and ACTH. Proc R Soc Med 43:769–773
Benedek TG (2011) History of the development of corticosteroid therapy. Clin Exp Rheumatol 29(suppl.68):5–12
Hollander JL, Brown EM, Jessar RA et al (1951) Hydrocortisone and cortisone injected into arthritic joints. JAMA 147:1629–1635
Freyberg RH, Traeger CH, Patterson M et al (1951) Problems of prolonged cortisone treatment for rheumatoid arthritis. JAMA 147:1538–1543
De Andrade JR, McCormick JN, Hill AGS (1964) Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis 23:158–162
Polley HF, Slocumb CH, Ward LE, Hench PS (1955) Recognition and treatment of patients with chronic hypercortisonism. Ann Rheum Dis 14:416–417
Pincus T, Cutolo M (2015) Clinical trials documenting the efficacy of low-dose-glucocorticoids in rheumatoid arthritis. Neuroimmunomodulation 22:46–50
Harris ED Jr, Emkey RD, Nichols JE, Newberg A (1983) Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 10:713–721
Kirwan JR (1995) The effects of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333:142–146
Boers M, Verhoeven AC, Markusse HM et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318
Everdingen AA van, Jacobs JWG, Reesema DRS van, Bijlsma JWJ (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. Ann Intern Med 136:1–12
Svensson B, Boonen A, Albertsson K et al (2005) Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52:3360–3370
Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52:3371–3380
Buttgereit F, Doering G, Schaeffler A et al (2008) Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371:205–214
Bakker MF, Jacobs JW, Welsing PM et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156:329–339
Montecucco C, Todoerti M, Sakellariou G et al (2012) Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 14:R112
Buttgereit F, Mehta D, Kirwan J et al (2013) Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 72:204–210
Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–735
Goes MC van der, Jacobs JW, Jurgens MS et al (2013) Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int 24:1429–1436
Weber G, Keitel W (1973) Die Kortisonoidbehandlung der rheumatoiden Arthritis. Mitteilungsbl Inst Rheum Dresd 11:8
Weber G, Keitel W (1975) Ergebnisse der Kortisonoid-Dosisreduktion bei Rheumatoider Arthritis. Dtsch Gesundheitsw 30:924–927
Huscher D, Deutsches Rheumaforschungszentrum, persönliche Mitteilung, 2.3.2016
Albrecht K, Callhoff J, Schneider M, Zink A (2015) High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort. Rheumatol Int 35:1377–1384
Ter Wee MM, Uyl D den, Boers M et al (2015) Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1‑year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 74:1233–1240
Smolen JS, Landewé R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509
Smolen JS, Landewé R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975
Gaujoux-Viala C, Nam JL, Ramiro S et al (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib—a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73:510–515
Strehl C, Bijlsma JWJ, Wit M de et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm in chronic inflammatory rheumatic diseases: A point of view from an EULAR task force. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-208916
Ramamoorthy S, Cidlowski JA (2016) Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am 42:15–31
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
E. Gromnica-Ihle gibt an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.
Additional information
Redaktion
U. Müller-Ladner, Bad Nauheim
H.-M. Lorenz, Heidelberg
M. Schneider, Düsseldorf
Rights and permissions
About this article
Cite this article
Gromnica-Ihle, E. Glukokortikoide. Z Rheumatol 75, 591–594 (2016). https://doi.org/10.1007/s00393-016-0115-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-016-0115-1